Monoclonal antibodies towards IGF-1R have similarly been studied in NSCLC and other tumor cell lines in vitro as well as in vivo in xenografts and revealed to have anti-tumor activity when used alone but more promptly when combined with IGF-1R TKI, radiotherapy or chemotherapy in which they are reported to cause clear IGF-1Rβ degradation [19-21, 25-28]. The gene discussed is IGF1R; the disease is neoplasm.